Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001104659-25-034310
Filing Date
2025-04-11
Accepted
2025-04-11 20:32:02
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 21703
2 EXHIBIT 99.(A) tm2512153d1_ex99-a.htm EX-99.(A) 4622
3 EXHIBIT 99.(B) tm2512153d1_ex99-b.htm EX-99.(B) 111231
  Complete submission text file 0001104659-25-034310.txt   139220
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91484 | Film No.: 25834022
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738
Business Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 512-254-3790
ADAR1 Capital Management, LLC (Filed by) CIK: 0001940272 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D